Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave

The neutralizing monoclonal antibody combination of tixagevimab/cilgavimab has been shown to reduce the risk of SARS-CoV-2 infection in unvaccinated individuals during the Alpha (B.1.1.7) and Delta (B.1.617.2) waves. However, data on the efficacy and safety of tixagevimab/cilgavimab in vaccinated so...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Jurdi, Ayman, Morena, Leela, Cote, Mariesa, Bethea, Emily, Azzi, Jamil, Riella, Leonardo V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906353/
https://www.ncbi.nlm.nih.gov/pubmed/35727916
http://dx.doi.org/10.1111/ajt.17128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906353/
https://www.ncbi.nlm.nih.gov/pubmed/35727916
http://dx.doi.org/10.1111/ajt.17128

Ejemplares similares